RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE

Gilead Sciences Liabilities 2024

Gilead Sciences Liabilities

39.29 B USD

Gilead Sciences Dividend yield

4.53 %

Ticker

GILD

ISIN

US3755581036

WKN

885823

In 2024, Gilead Sciences's total liabilities amounted to 39.29 B USD, a -6.29% difference from the 41.93 B USD total liabilities in the previous year.

Gilead Sciences Aktienanalyse

What does Gilead Sciences do?

Gilead Sciences Inc, also known as Gilead, is an American biopharmaceutical company specializing in the development and production of drugs. It was founded in 1987 by Michael Riordan and has since become one of the largest biopharmaceutical companies in the world. Gilead focuses on developing drugs for difficult-to-treat diseases such as HIV, hepatitis, cancer, and inflammatory diseases. Its business model is divided into three segments: HIV, liver diseases, and oncology. The company has made significant advancements in antiviral therapies and aims to improve patients' lives and cure diseases through the development of new medical products and therapies. In the HIV segment, Gilead offers drugs such as Truvada, Atripla, and Biktarvy. In liver diseases, the company has focused on fighting hepatitis C and offers drugs like Harvoni, Sovaldi, and Epclusa. In the field of oncology, Gilead develops drugs for cancer treatment, particularly targeting specific mutations. The company has made notable progress in this area, such as developing the first approved CAR-T-cell therapy for lymphoma treatment, Yescarta. Gilead has also gained attention through its innovative research and development work, including licensing the CRISPR-Cas9 technology for targeted gene editing. Overall, Gilead Sciences Inc has had a remarkable success story and is considered one of the most significant biopharmaceutical companies globally, setting standards and bringing hope for cure to many people with serious illnesses. Gilead Sciences ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Gilead Sciences revenue by segment

In the annual report of the Gilead Sciences share (US3755581036, 885823, GILD), it breaks down its revenues into 1 segments: 1. innovative Medicines. The Gilead Sciences stock (WKN: 885823, ISIN: US3755581036, Ticker Symbol: GILD) is a leading investment for investors interested in participating in the Health Care sector.

Liabilities Details

Assessing Gilead Sciences's Liabilities

Gilead Sciences's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Gilead Sciences's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing Gilead Sciences's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

Gilead Sciences's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in Gilead Sciences’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about Gilead Sciences Stock

What is the level of liabilities of Gilead Sciences this year?

Gilead Sciences has a debt balance of 39.29 B USD this year.

What were the liabilities of Gilead Sciences compared to the previous year?

The liabilities of Gilead Sciences have increased by -6.29% dropped compared to the previous year.

What are the consequences of high debt for investors of Gilead Sciences?

High liabilities can pose a risk for investors of Gilead Sciences, as they can weaken the company's financial position and impair its ability to meet its obligations.

What consequences do low liabilities have for investors in Gilead Sciences?

Low liabilities mean that Gilead Sciences has a strong financial position and is able to meet its obligations without overburdening its finances.

How does an increase in liabilities of Gilead Sciences affect the company?

An increase in liabilities of Gilead Sciences can lead to the company having more obligations and potentially find it more difficult to meet its financial commitments.

How does a reduction in the liabilities of Gilead Sciences affect the company?

A decrease in the liabilities of Gilead Sciences can lead to the company having fewer obligations and a stronger financial position, which can make it easier for the company to fulfill its financial commitments.

What are some factors that influence the liabilities of Gilead Sciences?

Some factors that can influence the liabilities of Gilead Sciences include investments, acquisitions, operating costs, and sales development.

Why is the level of liabilities of Gilead Sciences so important for investors?

The liabilities of Gilead Sciences are important for investors as they serve as an indicator of the company's financial stability and provide investors with information on how the company meets its financial obligations.

What strategic measures can Gilead Sciences take to modify the liabilities?

To change its liabilities, Gilead Sciences can take measures such as cost savings, increasing revenue, selling assets, raising investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to choose the best strategic actions.

How much dividend does Gilead Sciences pay?

Over the past 12 months, Gilead Sciences paid a dividend of 3 USD . This corresponds to a dividend yield of about 4.53 %. For the coming 12 months, Gilead Sciences is expected to pay a dividend of 0.63 USD.

What is the dividend yield of Gilead Sciences?

The current dividend yield of Gilead Sciences is 4.53 %.

When does Gilead Sciences pay dividends?

Gilead Sciences pays a quarterly dividend. This is distributed in the months of July, October, January, April.

How secure is the dividend of Gilead Sciences?

Gilead Sciences paid dividends every year for the past 15 years.

What is the dividend of Gilead Sciences?

For the upcoming 12 months, dividends amounting to 0.63 USD are expected. This corresponds to a dividend yield of 0.95 %.

In which sector is Gilead Sciences located?

Gilead Sciences is assigned to the 'Health' sector.

Wann musste ich die Aktien von Gilead Sciences kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Gilead Sciences from 3/28/2024 amounting to 0.77 USD, you needed to have the stock in your portfolio before the ex-date on 3/14/2024.

When did Gilead Sciences pay the last dividend?

The last dividend was paid out on 3/28/2024.

What was the dividend of Gilead Sciences in the year 2023?

In the year 2023, Gilead Sciences distributed 2.92 USD as dividends.

In which currency does Gilead Sciences pay out the dividend?

The dividends of Gilead Sciences are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Gilead Sciences stock can be added to a savings plan with the following providers: Trade Republic, ING, Scalable Capital and Consorsbank

Andere Kennzahlen von Gilead Sciences

Our stock analysis for Gilead Sciences Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Gilead Sciences Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.